The firm has been placing point-of-care systems primarily in the private sector, but may have increased access once it completes WHO prequalification review.
FIND will lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the assay's diagnostic accuracy and commercial utility.
The study is the first to demonstrate the design features and operational characteristics of Cepheid's Xpert MTB/RIF Ultra assay.
The partners are broadening their collaboration to bring point-of-care TB diagnostics to all levels of the health system in low- and middle-income countries.
The database of genotype, phenotype, and clinical data from multi-drug resistant TB cases may support improved diagnostic development and clinical decision making.
Grants awarded to Chembio, BD, and FIND will help fund new diagnostic tests for Ebola and other fever-inducing illnesses and feasibility studies to evaluate them.
A new study has found that an antigen-based rapid diagnostic test for Ebola could be more reliable under certain circumstances than a recently approved RT-PCR assay for the virus.
The new cartridge-based test runs on the firm's GeneXpert platform and provides a 90-minute molecular diagnosis of HIV in high-risk individuals and infants.
Cepheid is now considering adapting TB tests in development to cover the mutations, an executive told GenomeWeb.
Shipping of the assay, Cepheid's eighth product release in 2014, is anticipated to begin in February 2015.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.